Alkermes' Narcolepsy Drug Shows Sustained Efficacy in Phase 2 Trial
Event summary
- Alkermes to present additional data from Vibrance-1 Phase 2 study of alixorexton at AAN 2026 Annual Meeting (April 18-22, 2026).
- Study showed clinically meaningful and statistically significant improvements in wakefulness, cognition, and fatigue in NT1 patients.
- Over 95% of participants (88 out of 92) completed the 13-week trial, with sustained improvements through the open-label extension.
- Alixorexton received Breakthrough Therapy designation from the FDA for NT1 treatment.
The big picture
Alkermes' positive Phase 2 data for alixorexton comes as the narcolepsy treatment landscape seeks more targeted therapies. The drug's selective orexin 2 receptor agonist mechanism offers a novel approach, potentially addressing unmet needs in wakefulness and cognitive functioning. The company's strategic focus on neuroscience aligns with broader industry trends toward precision treatments for sleep disorders.
What we're watching
- Regulatory Pathway
- Whether the FDA's Breakthrough Therapy designation will accelerate alixorexton's approval process for NT1.
- Clinical Validation
- How the Phase 3 Brilliance Studies will confirm the sustained efficacy and safety of alixorexton in NT1 and NT2 patients.
- Market Differentiation
- The pace at which Alkermes can position alixorexton as a differentiated treatment option in the narcolepsy market.
Related topics